**Bruel, Timothée. Elimination of HIV-1-infected cells by broadly neutralizing antibodies. Nature Communications. 26 Jan 2016.** [**http://www.nature.com/articles/ncomms10844**](http://www.nature.com/articles/ncomms10844)

This paper has dose-response curves for ADCC. I used these graphs to calculate the in vitro hill slope for ADCC. The supplement has in vitro EC50 values for VRC01 ADCC.

**Huang, Yangxin. Hierarchical Bayesian Methods for Estimation of Parameters in a Longitudinal HIV Dynamic System. Biometrics. Jun 2006.** [**http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2435289/**](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2435289/)

This publication informed by knowledge of HIV models as well as literature estimates for parameters.

**Li, Yuxing. Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01. Journal of Virology. 29 Jun 2011.** [**http://jvi.asm.org/content/85/17/8954.full**](http://jvi.asm.org/content/85/17/8954.full)

This publication informed by knowledge of the antibody, VRC01.

**Luo, Rutao. HIV Model Parameter Estimates from Interruption Trial Data including Drug Efficacy and Reservoir Dynamics. PLOS One. 16 Jul 2012.** [**http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0040198**](http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0040198)

This publication informed by knowledge of HIV models as well as literature estimates for parameters.

**Lynch, Rebecca. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Science Translational Medicine. 23 Dec 2015.** [**http://stm.sciencemag.org/content/7/319/319ra206**](http://stm.sciencemag.org/content/7/319/319ra206)

The Lynch study tested VRC01 in a therapeutic context in chronically HIV-infected patients not on ART. This publication includes graphs of viral load and antibody concentration over time for each patient. There are also in vitro IC80 calculations for each patient. The supplement of this publication has more specific patient data (initial viral loads, CD4+ counts, etc.).

**Perelson, Alan. Dynamics of HIV Infection of CD4+ T Cells. Mathematical Biosciences. Mar 1993.** [**http://www.ncbi.nlm.nih.gov/pubmed/8096155**](http://www.ncbi.nlm.nih.gov/pubmed/8096155)

This publication informed by knowledge of HIV models as well as literature estimates for parameters.

**Ramratnam, Bharat. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. The Lancet. 20 Nov 1999.** [**http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(99)02035-8/fulltext?version=printerFriendly**](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(99)02035-8/fulltext?version=printerFriendly)

This publication informed by knowledge of HIV models as well as literature estimates for parameters.

**Sampah, Maame. Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance. PNAS. 25 Mar 2011.** [**http://www.pnas.org/content/108/18/7613.long**](http://www.pnas.org/content/108/18/7613.long)

This publication further explains the concept of IIP and why the dose-response curve is important when considering potency of an antibody.

**Stafford, Max. Modeling Plasma Virus Concentration during Primary HIV Infection. Journal of Theoretical Biology. 28 Dec 1999. http://ac.els-cdn.com/S0022519300910762/1-s2.0-S0022519300910762-main.pdf?\_tid=672d043a-6567-11e6-9aea-00000aab0f01&acdnat=1471540726\_71d2802f4186485375aa65ec0a47fc7c**

This publication informed by knowledge of HIV models as well as literature estimates for parameters. I also used parameters from this paper as some baseline estimates during model fitting.

**Webb, Nicholas. Dose–response curve slope helps predict therapeutic potency and breadth of HIV broadly neutralizing antibodies. Nature Communications. 21 Aug 2015.** [**http://www.nature.com/articles/ncomms9443**](http://www.nature.com/articles/ncomms9443)

This paper explains the concept of IIP and has dose-response curves for VRC01 neutralization. The supplement contains hill slope data for VRC01 neutralization, which I averaged to get a mean hill slope.

**Zhou, Tongqing. Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01. Science. 13 Aug 2010.** [**http://science.sciencemag.org/content/329/5993/811.full**](http://science.sciencemag.org/content/329/5993/811.full)

This publication informed by knowledge of the antibody, VRC01.